| Project/Area Number |
21390372
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
MIYAZAKI Masaru 千葉大学, 大学院・医学研究院, 教授 (70166156)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KIMURA Fumio 千葉大学, 大学院・医学研究院, 准教授 (70334208)
SHIMIZU Hiroaki 千葉大学, 大学院・医学研究院, 講師 (80272318)
YOSHIDOME Hiroyuki 千葉大学, 大学院・医学研究院, 講師 (10312935)
KATO Atushi 千葉大学, 大学院・医学研究院, 助教 (70344984)
高野 重紹 千葉大学, 大学院・医学研究院, 助教 (20436380)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000)
Fiscal Year 2011: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2010: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2009: ¥11,830,000 (Direct Cost: ¥9,100,000、Indirect Cost: ¥2,730,000)
|
|---|
| Keywords | proteomics / 膵癌 / 胆道癌 / 腫瘍マーカー / リン酸化蛋白 / ERK / Proteomics / シグナル伝達物質 / 自己抗体複合体 |
|---|
| Research Abstract |
Intracellular phosphoprotein activation significantly regulatescancer progression. We investigated the serum phosphoprotein profile involved in pancreatic cancer by a novel approach that comprehensively measured serum phosphoproteins levels, and clinically applied this method to the detection of pancreatic cancer. We analyzed the serum phosphoproteins that comprised cancer cellular signal pathways by comparing sera from pancreatic cancer patients and benign controls including healthy volunteers and pancreatitis patients. Hierarchical clustering analysis between pancreatic cancer patients and healthy volunteers revealed differential pathway-specific profiles. In particular, the components of the extracellular signal-regulated kinase (ERK) signaling pathway were significantly increased in the sera from pancreatic cancer patients compared with healthy volunteers. The positive rate of p-ERKI/2 (82%) was found to be superior to that of CA19-9 (53%) for early stage pancreatic cancer. For the combination of these serum levels, the area under the receiver-operator-characteristics curves were showing significant ability to distinguish between the two populations in independent validation set, and between cancer and non-cancer populations in another validation set. The comprehensive measurement of serum cell signal phosphoproteins is useful for, the detection of pancreatic cancer. Further investigations will lead to the implementation of tailor-made molecular-targeted therapeutics.
|
